Dr. James S. Manuso is a biotechnology/pharmaceutical industry CEO and serial entrepreneur experienced in the foundation, management, financing, governance and sale of start-up, public, private, domestic and international companies with marketed
and R&D-stage products. Prior to his current appointment as CEO of Talfinium Investments Inc., he executed financings, M&A transactions and other deals for biotech and pharmaceutical companies in excess of $2 billion dollars. Dr. Manuso serves as a director on the boards of Ocuphire (NASDAQ: OCUP) and Morphogenesis, Inc.
Previously, Dr. Manuso served as CEO of Astex Pharmaceuticals (NASDAQ: ASTX), where he led the sale of the Company to Otsuka for $886M. In 2011, Dr. Manuso spun out Astex technology that enabled the foundation and financing of Tolero Pharmaceuticals, sold to Sumitomo for up to $780MM in 2017. Earlier in his career, Dr. Manuso co-founded and was General Partner of PrimeTech Partners, a biotechnology venture management partnership, from 1998 to 2002, and Managing General Partner of The Channel Group LLC, an international life sciences corporate advisory firm. Dr. Manuso was also president of Manuso, Alexander & Associates, Inc., management consultants and financial advisors to pharmaceutical and biotechnology companies.
Earlier in his career, Dr. Manuso served on the boards of The Biotechnology Industry Organization (BIO) and its Health Section Governing Board, Novelos, Merrion Pharmaceuticals Ltd. (MERR:IEX; Dublin, Ireland), Inflazyme Pharmaceuticals, Inc. (IZP-TSE; Vancouver, Canada), Symbiontics, Inc., (sold to BioMarin as ZyStor, Inc. for
$110 Million), Montigen Pharmaceuticals, Inc., Quark Pharmaceuticals, Inc., Galenica Pharmaceuticals, Inc., Supratek Pharma, Inc., and EuroGen, Ltd. (London, UK), where he was chairman. Dr. Manuso began his career as vice president and Director of Health Care Planning and Development for The Equitable Companies (now Group Axa), where he also served as Acting Medical Director.
Dr. Manuso earned a B.A. with Honors in Economics and Chemistry from New York University, a Ph.D. in Experimental Psychophysiology and Genetics from the Graduate Faculty of The New School University where he was a New School Scholar, a Certificate in Health Systems Management from Harvard Business School, and an
Executive MBA from Columbia Business School where he was an Equitable Companies Scholar.